January 1 - March 31

  • Net sales reached SEK 3,5 (5,5) million
  • Operating profit/loss totaled SEK -4,7 million (-3,1) million
  • Loss after taxes SEK -4,8 (-3,1) million
  • Earnings per share, SEK (basic and diluted) amounted to SEK -0,06 (-0,06)
  • Cash flow from operating activities amounted to SEK -6,6 (-5,5) million
  • Cash and cash equivalents amounted to SEK 6,9 (5,9) million as per March 31, 2024

Significant events during the period

  • New management team appointed on February 15
  • Schelin Catheters – new study published on February 27

Significant events after the end of the period

  • Two new studies with ProstaLund’s Schelin Catheter® presented at the EAU in Paris on April 8
  • Positive results from unannounced inspection by TÜV SÜD conducted on April 9-10
  • ProstaLund and Capio Specialistcenter AB signed a new agreement regarding disposable materials used in CoreTherm® treatments. The agreement is over 12 months, with an option to extend. The order value is approximately SEK 1,3 million over the contract period. The agreement replaces the previous agreement with Capio Specialistcenter AB.
  • Prostalund informed on May 16 that the Board of Directors intends to decide on a rights issue of units for an initial issue amount of around 29 MSEK
(SEK MILLION)JAN-MAR 2024JAN-MAR 2023JAN-DEC 2023JAN-DEC 2022
Net sales3,55,522,117,2
Gross Margin, %69,768,270,174,2
Operating profit/loss, EBIT-4,7-3,1-16,9-10,9
Cash flow from operating activites-6,6-5,5-23,7-16,4
Cash and cash equivalents6,95,915,011,9
Average number of employees6788

”Despite a weaker quarter in terms of sales, we are positive about the underlying treatments and needs of our customers and the continued interest in our stand-alone products from an international perspective”

Anders Kristensson
CEO, ProstaLund AB (publ)

Please see attached PDF for full report.

For further information, please contact:

Anders Kristensson, CEO
Tel. +46 (0) 769 42 12 16
Email: anders.kristensson@prostalund.com

About ProstaLund

ProstaLund AB (publ) is a Swedish medtech company with a headquartered in Lund that develops and markets innovative products for the treatment of Benign Prostatic Enlargement. The company has patented the CoreTherm® Concept treatment method, a customised thermal treatment for BPE (Benign Prostatic Enlargement). ProstaLund is listed on Nasdaq First North Growth Market and has approximately 4,000 shareholders. See also - www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-16 08:00 CEST.

Attachments

ProstaLund AB (publ) Interim Report Jan Mars 2024 ENG

© Modular Finance, source Nordic Press Releases